Cargando…

miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation

BACKGROUND: Some of prostate cancer cases could progress to be Castrate Resistant Prostate Cancer (CRPC). However it is still a challenge to early diagnose it since no reliable examination could be done except PSA, which has high variability. It is now known that miRNAs are involved in nearly all in...

Descripción completa

Detalles Bibliográficos
Autores principales: Seputra, Kurnia Penta, Purnomo, Basuki Bambang, Susianti, Hani, Kalim, Handono, Purnomo, Athaya Febriantyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Medical sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800573/
https://www.ncbi.nlm.nih.gov/pubmed/35197661
http://dx.doi.org/10.5455/aim.2021.29.266-269
_version_ 1784642290973671424
author Seputra, Kurnia Penta
Purnomo, Basuki Bambang
Susianti, Hani
Kalim, Handono
Purnomo, Athaya Febriantyo
author_facet Seputra, Kurnia Penta
Purnomo, Basuki Bambang
Susianti, Hani
Kalim, Handono
Purnomo, Athaya Febriantyo
author_sort Seputra, Kurnia Penta
collection PubMed
description BACKGROUND: Some of prostate cancer cases could progress to be Castrate Resistant Prostate Cancer (CRPC). However it is still a challenge to early diagnose it since no reliable examination could be done except PSA, which has high variability. It is now known that miRNAs are involved in nearly all inflammatory responses. Several malignancies in humans that specifically express miRNA have been detected and identified. The expression values of miRNA-21 also correlates with the occurrence of resistant castration of prostate cancer and metastases, therefore miRNA-21 is expected to be a biomarker to estimate the progression of cancer. OBJECTIVE: The purpose of this study was to analyze the expression values and cut-off markers of miRNA-21 as markers of CRPC progression. METHODS: This study used a retrospective cohort design with observational analysis. The forty-eight total sample was obtained from serum, then the RT-PCR was performed to obtain expression values of miRNA-21. Data were analyzed using One Way ANOVA to see the difference in the expression values of miRNA-21. Furthermore, to determine the cut-off analysis was carried out using the ROC curve. RESULTS: In the BPH group, an average expression value of miRNA-21 was 33,785±1.80 ng/dL, in the Prostate cancer group the average miRNA-21 was 34.51±1.32 ng/dL, while in the CRPC group, an average miRNA-21 was obtained, reaching to 34.51±1.32 ng/dL. The cut-off value of miRNA-21 from the BPH category was <33,595, PPV = 50%, NPV = 80% with a value of p = 0.081, the prostate Ca category was 33.595–35.21, PPV = 87.5%, NPV = 66.7% with p value = 0.003, while the value of miRNA-21 in the CRPC category was> 35.21, PPV = 80%, NPV = 58.3 with a value of p = 0.04. CONCLUSION: There is a significant difference in the expression values of miRNA-21 between BPH with CRPC and Prostate cancer and CRPC, therefore, miRNA-21 cut-off point is potential to differentiate the diagnosis.
format Online
Article
Text
id pubmed-8800573
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Academy of Medical sciences
record_format MEDLINE/PubMed
spelling pubmed-88005732022-02-22 miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation Seputra, Kurnia Penta Purnomo, Basuki Bambang Susianti, Hani Kalim, Handono Purnomo, Athaya Febriantyo Acta Inform Med Original Paper BACKGROUND: Some of prostate cancer cases could progress to be Castrate Resistant Prostate Cancer (CRPC). However it is still a challenge to early diagnose it since no reliable examination could be done except PSA, which has high variability. It is now known that miRNAs are involved in nearly all inflammatory responses. Several malignancies in humans that specifically express miRNA have been detected and identified. The expression values of miRNA-21 also correlates with the occurrence of resistant castration of prostate cancer and metastases, therefore miRNA-21 is expected to be a biomarker to estimate the progression of cancer. OBJECTIVE: The purpose of this study was to analyze the expression values and cut-off markers of miRNA-21 as markers of CRPC progression. METHODS: This study used a retrospective cohort design with observational analysis. The forty-eight total sample was obtained from serum, then the RT-PCR was performed to obtain expression values of miRNA-21. Data were analyzed using One Way ANOVA to see the difference in the expression values of miRNA-21. Furthermore, to determine the cut-off analysis was carried out using the ROC curve. RESULTS: In the BPH group, an average expression value of miRNA-21 was 33,785±1.80 ng/dL, in the Prostate cancer group the average miRNA-21 was 34.51±1.32 ng/dL, while in the CRPC group, an average miRNA-21 was obtained, reaching to 34.51±1.32 ng/dL. The cut-off value of miRNA-21 from the BPH category was <33,595, PPV = 50%, NPV = 80% with a value of p = 0.081, the prostate Ca category was 33.595–35.21, PPV = 87.5%, NPV = 66.7% with p value = 0.003, while the value of miRNA-21 in the CRPC category was> 35.21, PPV = 80%, NPV = 58.3 with a value of p = 0.04. CONCLUSION: There is a significant difference in the expression values of miRNA-21 between BPH with CRPC and Prostate cancer and CRPC, therefore, miRNA-21 cut-off point is potential to differentiate the diagnosis. Academy of Medical sciences 2021-12 /pmc/articles/PMC8800573/ /pubmed/35197661 http://dx.doi.org/10.5455/aim.2021.29.266-269 Text en © 2021 Kurnia Penta Seputra, Basuki Bambang Purnomo, Hani Susianti, Handono Kalim, Athaya Febriantyo Purnomo https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Seputra, Kurnia Penta
Purnomo, Basuki Bambang
Susianti, Hani
Kalim, Handono
Purnomo, Athaya Febriantyo
miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation
title miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation
title_full miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation
title_fullStr miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation
title_full_unstemmed miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation
title_short miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation
title_sort mirna-21 serum evaluation in bph, hormone sensitive prostate cancer, and castrate resistant prostate cancer: attempt for diagnostic biomarker evaluation
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800573/
https://www.ncbi.nlm.nih.gov/pubmed/35197661
http://dx.doi.org/10.5455/aim.2021.29.266-269
work_keys_str_mv AT seputrakurniapenta mirna21serumevaluationinbphhormonesensitiveprostatecancerandcastrateresistantprostatecancerattemptfordiagnosticbiomarkerevaluation
AT purnomobasukibambang mirna21serumevaluationinbphhormonesensitiveprostatecancerandcastrateresistantprostatecancerattemptfordiagnosticbiomarkerevaluation
AT susiantihani mirna21serumevaluationinbphhormonesensitiveprostatecancerandcastrateresistantprostatecancerattemptfordiagnosticbiomarkerevaluation
AT kalimhandono mirna21serumevaluationinbphhormonesensitiveprostatecancerandcastrateresistantprostatecancerattemptfordiagnosticbiomarkerevaluation
AT purnomoathayafebriantyo mirna21serumevaluationinbphhormonesensitiveprostatecancerandcastrateresistantprostatecancerattemptfordiagnosticbiomarkerevaluation